9.04.20
8 min. Read

New Teladongo merger details. Pear’s acquisitive study strategy.

Issue 068

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Amwell's IPO filing and the possible longterm repercussions of Amazon's move into voice biomarkers via its first wearable device, Halo. Here's what's happening this week:

  • Teladoc-Livongo revealed more information about their multi-billion dollar merger in a lengthy government

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Big buys Limbix. Better’s De Novo, pricing, GTM.
7.14.23
6 min. Read
MedRhythms InTandem now FDA-listed. Akili downloads.
7.07.23
6 min. Read
New Database: 150+ clinical trials for PDTs
6.30.23
6 min. Read
125 PDTs in pipelines. ICER expands into digital health
6.16.23
4 min. Read
Akili goes OTC. Pricing. New ISO DTx definition.
6.09.23
7 min. Read
Trials: Twill, Akili, Click. DiGA clawback leads to bankruptcy
6.02.23
6 min. Read
Pear bought Pear. New HCPCS attempts. Trials
5.26.23
8 min. Read
Pear sold for $6M. Woebot pauses PDTs. Swing-FDA
5.19.23
6 min. Read
Quest bought Pack Health for $123M cash. Trials
4.21.23
6 min. Read
New digital health CPT code hopefuls. Trials
4.14.23
5 min. Read
  • First
  • Previous
  • 1 of 18
  • Next
  • Last